Date:Jun 2 2022
Your Name: Kazutoshi Fujita
Manuscript Title: Management of patients with advanced prostate cancer in Japan: 'real-world' consideration of the
results from the Advanced Prostate Cancer Consensus Conference
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_x_None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone Phaizer	36 months  Educational global grand
3	Royalties or licenses	_xNone	
4	Consulting fees	_xNone	

5	Payment or honoraria for		
	lectures, presentations, speakers bureaus, manuscript writing or educational events	Jannsen Pharma	Honoraria for lectures
		Astrazeneca	Honoraria for lectures
		Astellas	Honoraria for lectures
		Ono Pharmaceutical	Honoraria for lectures
		Bristl-Meyers	Honoraria for lectures
		Takeda	Honoraria for lectures
		Phaizer	Honoraria for lectures
		Bayer	Honoraria for lectures
		Novartis	Honoraria for lectures
		Kissei	Honoraria for lectures
6	Payment for expert	x None	
	testimony		
	,		
7	Support for attending	xNone	
	meetings and/or travel		
8	Patents planned issued or	x None	
"	Patents planned, issued or pending	XNOTIC	
9	Participation on a Data	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Astellas	Advisory board
		Astellas	Advisory board
10	Leadership or fiduciary role	x None	
10	in other board, society,	xNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	x_None	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_xNone	
	financial interests	_	
		•	•

l received honoraria from Jannsen Pharmam, Astrazeneca, Astellas, Ono Pharmaceutical, Bristl-Meyers, Takeda,
Phaizer, Bayer, Novartis, and Kissei and received Educational global grand from Pfizer.

Please place an "X" next to the following statement to indicate your agreement:
_x I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	2 June 2022
Your Name:	Hiroyoshi Suzuki
<b>Manuscript Ti</b>	itle: <u>Management of patients with advanced prostate cancer in Japan: 'real-world' consideration of the</u>
results from t	he Advanced Prostate Cancer Consensus Conference
Manuscript no	umber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	<u>x</u> None	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_xNone	
	any entity (if not indicated	Takda	Institutional
	in item #1 above).	Nippon-Shinyaku	Institutional
		Bayer	Institutional
		Kissei	Institutional
		Sanofi	Institutional
		Daiichi-Sankyo	Institutional
		Taiho	Institutional

		Ono	Institutional
		Nihon-Kayaku	Institutional
		Astellas	Institutional
		Janssen	Institutional
		AstraZeneca	Institutional
3	Royalties or licenses	_xNone	mstrutional
,	Royalties of ficerises	_XNone	
4	Consulting fees	None	
•	consulting rees	Takeda	Personal
		Daiichi-Sankyo	Personal
		Janssen	Personal
		Bayer	Personal
5	Payment or honoraria for	None	i Cisoliai
,	lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	x None	
	testimony		
	,		
7	Support for attending	_xNone	
,	meetings and/or travel	_xnone	
	meetings and/or travel		
_			
8	Patents planned, issued or	_xNone	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or	Janssen	Personal
	Advisory Board	Bayer	Personal
		Sanofi	Personal
		AstraZeneca	Personal
		Eli-lily	Personal
		MSD	Personal
		Astellas	Personal
10	Leadership or fiduciary role	_xNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_xNone	
12	Receipt of equipment,	_xNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_xNone	
	financial interests		

I received grants from Takda, Nippon-Shinyaku, Bayer, Kissei, Sanofi, Daiichi-Sankyo, Taiho, Ono, Nihon-Kayaku, Astellas, Janssen, AstraZeneca and participated on a Data Safety Monitoring Board or Advisory Board in Janssen,
Bayer, Sanofi, AstraZeneca, Eli-lily, MSD and Astellas.

Please place an "X" next to the following statement to indicate your agreement:

\_ X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:June 23, 2022
Your Name:Nobuyuki Hinata
Manuscript Title: Management of patients with advanced prostate cancer in Japan: 'real-world' consideration of the
results from the Advanced Prostate Cancer Consensus Conference
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
	-		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
42	Descript of anythment	Niere	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

I have no financial relationships to disc	lose.	

Please place an "X" next to the following statement to indicate your agreement:

\_X I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

Date: 2-June-2022	
Your Name: Yuji Miura	
Manuscript Title: Management of patients with advanced prostate cancer in Japan: 'real-world' considerations and advanced prostate cancer in Japan: 'real-world' considerations are supported by the contract of the contract	on of the
results from the Advanced Prostate Cancer Consensus Conference	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	Institutional financial interest from MSD and Ono Pharmaceutical
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	Personal honoraria from Takeda, MSD, ONO pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	X_None	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	Takeda
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

Dr. Yuji Miura reports personal honoraria from Takeda, MSD, ONO pharmaceutical, Bristol-Myers Squibb,
Chugai Pharmaceutical, outside the submitted work; Institutional financial interest from MSD and ONO
pharmaceutical.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on the form.	ıis

Date:02/June/2022	
Your Name:Kohei Edamura	
Manuscript Title: Management of patients with advanced prostate cancer in Japan: 'real-world' cons	ideration of the
results from the Advanced Prostate Cancer Consensus Conference	
Manuscript number (if known):	
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below related to the content of your manuscript. "Related" means any relation with for-profit or not-for-proparties whose interests may be affected by the content of the manuscript. Disclosure represents a conto transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.	fit third
The following questions apply to the author's relationships/activities/interests as they relate to the cu	urrent

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	_vNone	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_ <b>/</b> None	
	testimony		
7	Support for attending meetings and/or travel	_ <b>/</b> _None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	<b>/</b> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<b>/</b> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	✓ None	
11	Stock of Stock options	None	
12	Receipt of equipment,	✓ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	VNone	
	financial interests		
Dlar	aca cummariza tha abaya ca	unflict of interact in the fall	owing hove

No COI			

Please place an "X" next to the following statement to indicate your agreement:

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 05 Jun 2022
Your Name: Ken-ichi Tabata
Manuscript Title: Management of patients with advanced prostate cancer in Japan: 'real-world' consideration of the
results from the Advanced Prostate Cancer Consensus Conference
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: nest	26 months
		Time frame: past	
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X	Janssen, MSD, AstraZeneca, Bayer, Astellas and Chugai
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	_x	Janssen, AstraZeneca, Bayer, MSD, Astellas, Sanofi and Kyowakirin
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
	testimony		
_			
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	X_	Janssen, Bayer and Takeda
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Janssen, MSD, AstraZeneca, Bayer, Astellas and Chugai, Sanofi, Kyowakirin and Takeda

Please place an "X" next to the following statement to indicate your agreement:

\_ X \_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	_4/June/2022		
Your Name:	Gaku Arai		
<b>Manuscript Title</b>	e:_ <u>Management o</u>	f patients with advanced prostate cancer in Japan: 'real-world'	consideration of the
results from the	e Advanced Prostat	te Cancer Consensus Conference	
Manuscript nur	nber (if known):		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	5 Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

None			

Please place an "X" next to the following statement to indicate your agreement:
\_X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:03-JUN-2022	
Your Name:	_Nobuaki Matasubara
Manuscript Title: _ M	anagement of patients with advanced prostate cancer in Japan: 'real-world' consideration of the
results from the Adva	anced Prostate Cancer Consensus Conference
Manuscript number	(if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	_	Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	into time initia for this term.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_	Janssen, AstraZeneca, Bayer, Roche, MSD, Taiho, Astellas, Amgen, Eisai, Eli Lilly, PRA Health Science, Takeda, Pfizer, Seagen, Chugai, Abbvie and Novartis
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	_x_	Janssen, Sanofi
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	_x_	Janssen, AstraZeneca, MSD, Roche, Eli Lilly, Amgen,
	Safety Monitoring Board or Advisory Board		Pfizer, Chugai and Seagen
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

NM received speaker bureau from Janssen and Sanofi, and received research funding for institution from Janssen, AstraZeneca, Bayer, Roche, MSD, Taiho, Astellas, Amgen, Eisai, Eli Lilly, PRA Health Science, Takeda, Pfizer, Seagen,
Chugai, Abbvie and Novartis.

Please place an "X" next to the following statement to indicate your agreement:
_X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

I have no financial relationships to disclose.	

Please place an "X" next to the following statement to indicate your agreement:

\_X I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

Date: <u>2/Jun/ 2022</u>
Your Name: Takeo Kosaka
Manuscript Title: Management of patients with advanced prostate cancer in Japan: 'real-world' consideration of the
results from the Advanced Prostate Cancer Consensus Conference
Manuscript number (if known):
•

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
	-		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
42	Descript of anythment	Niere	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

None			

Please place an "X" next to the following statement to indicate your agreement:

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

Date:	03-JUN-2022	
Your Name:	Mototsugu Oya	
Manuscript Title:	Management of patients wit	n advanced prostate cancer in Japan: 'real-world' consideration of the
results from the A	Advanced Prostate Cancer Cons	sensus Conference
Manuscript numb	oer (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	☑_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	Astellas
3	Royalties or licenses	_☑_None	
4	Consulting fees	☑_None	

5	Payment or honoraria for lectures, presentations,	None	Astellas, Sanofi, Janssen, Astrazeneca, Takeda, Bayer, MSD
	speakers bureaus,		mod
	manuscript writing or educational events		
6	Payment for expert	_☑_None	
	testimony		
7	Support for attending meetings and/or travel	_☑_None	
8	Patents planned, issued or	_ <b>∠</b> Z_None	
	pending		
9	Participation on a Data Safety Monitoring Board or	_☑_None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	☑_None	
	group, paid or unpaid		
11	Stock or stock options	_☑_None	
12	Receipt of equipment,	_ <b>∠</b> Z_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_☑_None	
	financial interests		
Plea	ase summarize the above co	nflict of interest in	the following box:

Dr. Mototsugu Oya reports personal honoraria from Astellas, Sanofi, Janssen, Astrazeneca, Takeda, Bayer and and received research funding for Astellas.	MSD,

Please place an "X" next to the following statement to indicate your agreement:

\_ X \_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

Date:	02 June 2, 2022	
Your Name:	Mikio Sugimoto	
Manuscript Title: _ Ma	nagement of patients with advance	d prostate cancer in Japan: 'real-world' consideration of the
results from the Adva	nced Prostate Cancer Consensus Cor	nference
Manuscript number (i	f known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None None	planning of the work		
Time frame: past 36 months					
2	Grants or contracts from any entity (if not indicated in item #1 above).	None			
3	Royalties or licenses	None			
4	Consulting fees	None			

5	Payment or honoraria for lectures, presentations, speakers bureaus,	Janssen				
		Astellas				
		Astra Zeneca				
	manuscript writing or					
	educational events					
6	Payment for expert	None				
	testimony					
7	Cupport for attending	None				
/	Support for attending meetings and/or travel	None				
	meetings and/or traver					
8	Patents planned, issued or	None				
	pending					
9	Participation on a Data	None				
	Safety Monitoring Board or					
10	Advisory Board					
10	Leadership or fiduciary role	None				
	in other board, society, committee or advocacy					
	group, paid or unpaid					
11	Stock or stock options	None				
	•					
12	Receipt of equipment,	None				
	materials, drugs, medical					
	writing, gifts or other					
12	services					
13	Other financial or non-	None				
	financial interests					
Please summarize the above conflict of interest in the following hox:						

Honoraria for lecture from Janssen, Astellas, AstraZeneca			

Please place an "X" next to the following statement to indicate your agreement:

\_\_X I certify that I have answered every question and have not altered the wording of any of the questions on this

form.